Just Because a Drug is FDA Approved Doesn't Mean it Works

The video is the final episode in a series on drug approval in the U.S., discussing the FDA's standards, controversies like Adjihelm, and the Right to Try Act. It explores differing opinions on whether the FDA is too risk-averse or lenient, highlighting issues like increased clinical trial costs and the opioid crisis. The video concludes with a preference for the FDA's expanded access over the Right to Try Act, emphasizing the need for verifying clinical efficacy post-approval.

Discuss the controversy surrounding the approval of Adjihelm and the implications of surrogate endpoints.

What are the potential risks associated with the opioid crisis in relation to FDA approvals?

In your opinion, what should be the balance between safety oversight and access to investigational drugs for terminally ill patients?